SNTI

Senti Bioscience

0.9617

+0.0266+2.84%

Pre Market: 1.050 +0.088 +9.18%06:48 04/17 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.9500/0.9351

TODAY RANGE0.8900-0.9685

VOL98.47K

MARKET CAP29.95M

52 WEEK RANGE0.7702-5.10

AVG VOL (3M)163.44K

% TURNOVER0.29%

TURNOVER0

P/E (TTM)-0.3519

% RANGE8.38%

EPS(TTM)-2.7326

P/E(FORWARD)-1.0123

P/B5.31

BVPS0.1810

DIVIDEND--

P/S1,373.86

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP11.03M

SHARES OUTSTANDING31.14M

NEXT EARNINGS05/06-05/12

FREE FLOAT11.47M

LOT SIZE1

EX-DATE07/18/2024

News

Press Releases

Financial Reports

Profile

PUBT·3d ago
Senti Bio CEO Timothy Lu to present logic-gated NK cell therapy at AACR meeting
TipRanks·04/01 21:34
Senti Biosciences Plans Tax-Free Holding Company Reorganization
Reuters·04/01 20:34
Senti Biosciences plans tax-free holding company reorganization by April 16
Reuters·04/01 20:33
SENTI BIOSCIENCES, INC: UPON EFFECTIVENESS OF HOLDING COMPANY REORGANIZATION, SENTI BIOSCIENCES HOLDINGS WOULD BECOME SUCCESSOR ISSUER TO CO
Reuters·04/01 20:33
SENTI BIOSCIENCES INC - ANNOUNCES HOLDING COMPANY REORGANIZATION EFFECTIVE BY APRIL 16, 2026 - SEC FILING
Reuters·04/01 12:45
Senti Bio study in Cell Systems advances NOT-gated CAR design for T and NK therapies
Dow Jones·03/30 12:07
Senti Biosciences Price Target Cut to $11.00/Share From $13.00 by Chardan Capital
Dow Jones·03/30 12:07
Senti Biosciences Is Maintained at Buy by Chardan Capital
TipRanks·03/28 03:55
Buy Rating on SENTI-202 Driven by Strong Early AML Efficacy and De-Risking Regulatory Designations Despite Financing Overhang
TipRanks·03/27 12:20
Senti Bio reports Q4 EPS (53c), consensus (47c)
Reuters·03/27 12:11
Senti Biosciences Q4 revenue misses analyst estimates
Seeking Alpha·03/27 12:05
Senti Biosciences Non-GAAP EPS of -$0.53 misses by $0.06
Dow Jones·03/27 12:03
*Senti Biosciences 4Q Loss/Shr 53c >SNTI
Reuters·03/27 12:01
Senti Biosciences FY2025 net loss widens 16.38% to $61 million; revenue rises to $22,000
Reuters·03/27 12:00
BRIEF-Senti Biosciences Q4 Net Income USD -14.467 Million

Same Industry

Name/Symbol

Change%

Price

SNTI

Regeneron Pharmaceuticals

REGN

-2.47%

748.87

GRDX

BIONTECH

BNTX

+1.49%

99.88

United Therapeutics Corp.

UTHR

-0.53%

571.73

Vertex Pharmaceuticals Inc

VRTX

-1.37%

435.65

SIGA

Moderna

MRNA

-0.62%

50.96

Charles Riv Labs Intl Inc

CRL

+0.06%

175.65

Medpace Holdings

MEDP

-0.56%

515.65

Talphera Inc

TLPH

-6.35%

0.7606

ICON PLC

ICLR

+2.36%

112.97

CBPO

Iqvia Hldgs Inc

IQV

-0.97%

167.34

MOLN

Arcturus Therape

ARCT

+0.06%

8.69

Gilead Sciences Inc

GILD

-2.18%

138.99

PRA Health

PRAH

0.00%

165.21

Incyte Corp

INCY

-0.92%

96.07

APVO

BSTC

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.